Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.37 |
| ▸ | JAK1 | P23458 | 5/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346283 | 0.86 | SMN1; SMN2 (0.38) | SMN1; SMN2USP2CTSKJAK2JAK1 | |
| SCHEMBL18416945 | 0.84 | USP2 (0.42) | SMN1; SMN2USP2CTSKJAK2JAK1 | |
| SCHEMBL17176713 | 0.84 | USP2 (0.42) | SMN1; SMN2USP2CTSKJAK2JAK1 | |
| SCHEMBL346526 | 0.83 | HTT (0.36) | SMN1; SMN2USP2CTSKJAK2JAK1 | |
| SCHEMBL16553695 | 0.82 | ALDH1A1 (0.40) | SMN1; SMN2CTSKJAK1GPR119ALDH1A1 | |
| SCHEMBL14085878 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2CTSKJAK1GPR119ALDH1A1 | |
| SCHEMBL3530835 | 0.80 | GPR119 (0.42) | JAK2JAK1GPR119KMT2A | |
| SCHEMBL4407528 | 0.80 | TSHR (0.47) | JAK2JAK1 | |
| SCHEMBL2636236 | 0.78 | APP (0.46) | JAK2JAK1 | |
| SCHEMBL16554255 | 0.78 | MEN1 (0.44) | SMN1; SMN2JAK2JAK1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357925-B1 | SALT TYPE AND CRYSTAL TYPE OF 4H-PYRAZOLO [1, 5-ALPHA]BENZIMIDAZOLE COMPOUND AND PREPARATION METHOD AND INTERMEDIATE THEREOF | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3357925-B1 | SALT TYPE AND CRYSTAL TYPE OF 4H-PYRAZOLO [1, 5-ALPHA]BENZIMIDAZOLE COMPOUND AND PREPARATION METHOD AND INTERMEDIATE THEREOF | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10941150-B2 | Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2021-03-09 | — | — | US | disclosed |
| US-10941150-B2 | Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2021-03-09 | — | — | US | disclosed |
| CN-108137598-B | Salt form and crystal form of 4H-pyrazolo [1, 5-alpha ] benzimidazole compound, and preparation method and intermediate thereof | 湖北生物医药产业技术研究院有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-10428073-B2 | Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2019-10-01 | — | — | US | disclosed |
| US-10428073-B2 | Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2019-10-01 | — | — | US | disclosed |
| EP-3130592-B1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3130592-B1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2019-08-14 | — | — | EP | disclosed |
| US-20180258093-A1 | SALT TYPE AND CRYSTAL TYPE OF 4H-PYRAZOLO [1, 5-ALPHA] BENZIMIDAZOLE COMPOUND AND PREPARATION METHOD AND INTERMEDIATE THEREOF | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2018-09-13 | — | — | US | disclosed |
| EP-3130592-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| WO-2015154630-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-Α]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | 南京明德新药研发股份有限公司 | 2015-10-15 | — | — | WO | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| EP-1761491-A1 | NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006001752-A1 | NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258093-A1 | SALT TYPE AND CRYSTAL TYPE OF 4H-PYRAZOLO [1, 5-ALPHA] BENZIMIDAZOLE COMPOUND AND PREPARATION METHOD AND INTERMEDIATE THEREOF | REN, BRI3BP, SCN4A | SMN1; SMN2 4312/4885USP2 4510/4885CTSK 2978/4885 |
| US-10941150-B2 | Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | BRI3BP, REN, SCN4A | SMN1; SMN2 4149/4885USP2 4393/4885CTSK 3127/4885 |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | PARP1, PARP2, PARP11 | SMN1; SMN2 3180/4885USP2 4160/4885CTSK 1764/4885 |
| US-10428073-B2 | Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | REN, BRI3BP, KCNJ11 | SMN1; SMN2 4361/4885USP2 4567/4885CTSK 2826/4885 |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | CCR5, CXCR1, CCR2 | SMN1; SMN2 4558/4885USP2 4378/4885CTSK 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.